High CSF total tau levels were associated with faster loss of cognitive dysfunction in an AD cohort independent of their AD stage in a study by Duits et al. (26), but also in non-demented subjects—evidence suggests that different tau-level subgroups may reflect distinct underlying biological processes and that tau levels are not markers of disease progression per se. This evidence concerns the gene MAPT and Alzheimer disease.